Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

PURPOSE: In a recent phase II study of onartuzumab (MetMAb), patients whose non–small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. We describe development and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Koeppen, Hartmut, Yu, Wei, Zha, Jiping, Pandita, Ajay, Penuel, Elicia, Rangell, Linda, Raja, Rajiv, Mohan, Sankar, Patel, Rajesh, Desai, Rupal, Fu, Ling, Do, An, Parab, Vaishali, Xia, Xiaoling, Januario, Tom, Louie, Sharianne G., Filvaroff, Ellen, Shames, David S., Wistuba, Ignacio, Lipkind, Marina, Huang, Jenny, Lazarov, Mirella, Ramakrishnan, Vanitha, Amler, Lukas, Phan, See-Chun, Patel, Premal, Peterson, Amy, Yauch, Robert L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504679/
https://ncbi.nlm.nih.gov/pubmed/24687921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1836
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados